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Anticonvulsant activitiesAbstract Novel 3-(4,6-dimethoxybenzofuran-5-yl)-1-phenyl-1H-pyrazole-4-carboxaldehyde (3)
and 3-chloro-3-(4,6-dimethoxybenzofuran-5-yl)propenal (4) were prepared via Vilsmeier–Haack
reaction of 1-(4,6-dimethoxybenzofuran-5-yl)ethanone (1) and its hydrazone derivative 2. Reaction
of compound 4 with some hydrazine derivatives, namely hydrazine hydrate, phenylhydrazine and
benzylhydrazine hydrochloride led to the formation of pyrazole derivatives 5–8, respectively. On
the other hand, reaction of compound 4 with thiourea, urea or guanidine gave the pyrimidine deriv-
atives 9–11, respectively. Reaction of amino compound 11 with acetic anhydride, benzoyl chloride
and benzenesulphonyl chloride yielded N-substituted pyrimidine derivatives 12–14, respectively.
Reaction of diazonium salt of compound 11 with sodium azide afforded azidopyrimidine derivative
15, which upon reaction with ethyl acetoacetate gave 1,2,3-triazole derivative 16. Acid catalyzed
reaction of 11 with p-nitrobenzaldehyde gave Schiff base 17, which cyclized upon reaction with thio-
glycolic acid or chloroacetyl chloride to give thiazolidin-4-one 18 and azetidin-2-one 19, respec-
tively. The newly synthesized compounds were tested for their anti-inﬂammatory, analgesic and
anticonvulsant activities. Depending on the obtained results, the newly synthesized compounds pos-
sess signiﬁcant anti-inﬂammatory, analgesic and anticonvulsant activities.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Vilsmeier–Haack reaction is a widely used method for the
formylation of activated aromatic and heteroaromatic com-
pounds (Vilsmeier and Haack, 1927). The reactions of ali-
phatic substrates, particularly carbonyl compounds (Thomas
Synthesis, anti-inﬂammatory, analgesic and anticonvulsant activities 915et al., 2004) and their hydrazones (Kira et al., 1969) with
chloromethyleneiminium salts are highly versatile. They lead
to multiple iminoalkylations in the presence of excess reagent
and the resulting intermediates undergo cyclization to afford
aromatic or heterocyclic compounds (El-Sawy et al., 2007;
Quiroga et al., 2008; Damjanovic et al., 2009; Prakash et al.,
2011). Furthermore, the reactions of methylene active com-
pounds with chloromethyleneiminium salts lead mainly to
the formation of b-haloencarboxaldehyde derivatives (Meesala
and Nagarajan, 2006; Herbivo et al., 2009) which are useful
precursors in the construction of different heterocyclic com-
pounds (Meesala and Nagarajan, 2006; Herbivo et al., 2009;
Paul et al., 2001; Park et al., 2005; Hegab and Abdulla,
2006; Hegab et al., 2008). On the other hand, benzofuran
derivatives occupy a position of considerable signiﬁcance for
widespread occurrence in plants and their potential as impor-
tant pharmaceuticals (Mandour et al., 1996; El-Shihi et al.,
2005; Banskota et al., 2000; Choi et al., 2008; Liu et al.,
2011). Literature revealed that pyrazole and pyrimidine are
known for their pronounced pharmaceutical activities (Farag
et al., 2008; Menozzi et al., 2003; El-Sawy et al., 2013). So,
the goal of this work is the synthesis of some new benzofurans
containing substituted pyrazole and pyrimidine moieties at
their 5-position and evaluating their anti-inﬂammatory, anal-
gesic and anticonvulsant activities.
2. Experimental
2.1. Chemistry
Melting points were determined in open capillary tubes on an
Electrothermal 9100 digital melting point apparatus (Mount
Holly, New Jersey, USA) and are uncorrected. Elemental anal-
yses were performed on a Perkin–Elmer 2400 analyzer (Perkin-
Elmer, USA) and were found within ±0.4 % of the theoretical
values. IR spectra were recorded on a Perkin–Elmer 1600
FTIR (Perkin–Elmer, USA) in KBr discs. The 1H and 13C
NMR spectra were recorded on Bruker spectrometer (500
and 125 MHz) (Bruker, Germany) in DMSO-d6, and chemical
shifts were recorded in d ppm relative to the internal standard
solvent TMS. Mass spectra (EI) were run at Gas Chromato-
graph Mass Spectrometer, single phase, 200 V, 50/60 Hz,
30 A (Jeol Ltd., Japan).
Visnagin was purchased from Chemical Industrial Develop-
ing Company (CID), Giza, Egypt. The starting 1-(4,6-dime-
thoxy benzofuran-5-yl) ethanone (1) was prepared via the
alkaline hydrolysis of visnagin followed by methylation with
dimethyl sulphate (Schonberg et al., 1953).
2.1.1. 1-(1-(4,6-Dimethoxybenzofuran-5-yl)ethylidene)-2-
phenylhydrazine (2)
A mixture of 1-(4,6-dimethoxybenzofuran-5-yl)ethanone (1)
(1 g, 0.0042 mol) and phenylhydrazine (0.45 g, 0.0042 mol) in
glacial acetic acid (20 mL) was reﬂuxed for 2 h. After cooling,
the reaction mixture was poured onto water (50 mL) and the
solid that formed was ﬁltered off, washed with water, air dried
and recrystallized from absolute ethanol. Yield 85 %, m.p.
104–6 C. IR (KBr): m 3100 (NH), 1636 (C‚N), 1568
(C‚C), 1066, 1018, 1009 cm1 (C–O–C). 1H NMR
(500 MHz, DMSO-d6, 25 C, TMS): d= 2.01 (s, 3H, CH3),
3.78 & 3.95 (2s, 6H, 2OCH3), 7.08 (s, 1H, H-7), 7.01–7.20(m, 5H, Ar–H), 7.86 (d, 1H, H-3), 7.89 (d, 1H, H-2),
8.15 ppm (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6,
25 C, TMS): d= 18.2 (CH3), 59.4 & 60.5 (2OCH3), 89.9 (C-
7), 104.9–157.2 ppm (Ar–C). Anal. For C18H18N2O3 (310.35)
calcd: C 69.66, H 5.56, N 9.03. Found: C 69.45, H 5.32, N 8.99.
2.1.2. 3-(4,6-Dimethoxybenzofuran-5-yl)-1-phenyl-1H-
pyrazole-4-carboxaldehyde (3)
To a solution of compounds 2 (0.93 g, 0.003 mol) in dimethyl-
formamide (15 mL), phosphorus oxychloride (1.17 mL,
0.01 mol) was added dropwise at 0 C while stirring. After
complete addition of POCl3, the reaction mixture was left to
stir for 15 h, and then poured onto ice-water (20 mL). The so-
lid that formed was ﬁltered off, air dried and recrystallized
from absolute ethanol. Yield 84 %, m.p. 59–61 C. IR
(KBr): m 1705 (C‚O), 1640 (C‚N), 1569 (C‚C), 1102,
1084, 1055 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-d6,
25 C, TMS): d= 3.69 & 3.89 (2s, 6H, 2OCH3), 7.01 (m,
5H, Ar–H), 7.50 (s, 1H, H-7), 7.53 (d, 1H, H-3), 7.91 (d, 1H,
H-2), 9.02 (s, 1H, H-5 pyrazole), 9.55 ppm (s, 1H, CHO).
13C NMR (125 MHz, DMSO-d6, 25 C, TMS): d= 56.1 &
60.5 (2OCH3), 89.7 (C-7), 104.9–157.2 (Ar–C), 201.1 ppm
(C‚O). MS, m/z (%): 348 (M+, 2), 77 (100). Anal. For
C20H16N2O4 (348.35) calcd: C 68.96, H 4.63, N 8.03. Found:
C 69.00, H 4.44, N 7.89.
2.1.3. 3-Chloro-3-(4,6-dimethoxybenzofuran-5-yl)propenal (4)
To a solution of compound (1) (1 g, 0.0042 mol) in dimethyl-
formamide (15 mL), phosphorus oxychloride (1.17 mL,
0.012 mol) was added dropwise at 0 C while stirring. After
complete addition of POCl3, the reaction mixture was warmed
to room temperature and then heated at 60 C for 3 h. After
cooling, the reaction mixture was poured onto crushed ice and
then neutralized with 10% aqueous sodium hydroxide solution.
The precipitate that formed was ﬁltered off, washed with water,
air dried and recrystallized from methanol. Yield 30 %, m.p.
118–120 C. IR (KBr): m 1722 (C‚O), 1585 (C‚C), 1085,
1054, 1005 (C–O–C), 739 cm1 (Cl). 1H NMR (500 MHz,
DMSO-d6, 25 C, TMS): d= 3.89 & 4.11 (2s, 6H, 2OCH3),
6.82 (d, 1H, CH‚), 7.05 (s, 1H, H-7), 7.18 (d, 1H, H-3)
7.90 (d, 1H, H-2), 9.51 ppm (d, 1H, CHO). 13C NMR
(125 MHz, DMSO-d6, 25 C, TMS): d= 56.2 & 59.9
(2OCH3), 89.7 (C-7), 105.3–156.7 (Ar–C), 201.1 ppm (C‚O).
MS, m/z (%): 268 (M++2, 20), 266 (M+, 7), 238 (100). Anal.
For C13H11ClO4 (266.68) calcd: C 58.55, H 4.16. Found: C
58.33, H 4.44.
2.1.4. 5-(4,6-Dimethoxybenzofuran-5-yl)-1H-pyrazole (5)
A mixture of compound 4 (0.53 g, 0.002 mol) and hydrazine
hydrate 99% (0.1 g, 0.002 mol) in absolute ethanol (15 mL)
containing few drops of glacial acetic acid was reﬂuxed for
3 h. After cooling, the reaction mixture was poured onto water
(20 mL) and the solid that formed was ﬁltered off, air dried
and recrystallized from methanol. Yield 77 %, m.p. 69–
72 C. IR (KBr): m 3100 (NH), 1637 (C‚N), 1606 (C‚C),
1062, 1020 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-d6,
25 C, TMS): d= 3.89 & 4.11 (2s, 6H, 2OCH3), 6.81 (d, 1H,
CH), 7.01 (s, 1H, H-7), 7.06 (d, 1H, CH), 7.18 (d, 1H, H-3),
8.02 (d, 1H, H-2), 8.51 ppm (s, 1H, NH). 13C NMR
(125 MHz, DMSO-d6, 25 C, TMS): d= 56.2 & 59.9
(2OCH3), 89.7 (C-7), 104.1–156.3 ppm (Ar–C). Anal. For
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C 64.00, H 4.74, N 11.23.
2.1.5. 1-(5-(4,6-Dimethoxybenzofuran-5-yl)-1H-pyrazol-1-
yl)ethanone (6)
To a solution of compound 4 (0.53 g, 0.002 mol) in a mixture
of (10 mL) acetic anhydride and glacial acetic acid (2:1) was
added hydrazine hydrate 99% (0.1 mL, 0.002 mol). The reac-
tion mixture was reﬂuxed for 4 h. After cooling, the reaction
mixture was poured onto ice-water (50 mL), and the solid that
formed was ﬁltered off, air dried and recrystallized from aque-
ous ethanol. Yield 65 %, m.p. 128–130 C. IR (KBr): m 1699
(C‚O), 1624 (C‚N), 1567 (C‚C), 1010, 1009, 1001 cm1
(C–O–C). 1H NMR (500 MHz, DMSO-d6, 25 C, TMS):
d= 2.39 (s, 3H, CH3), 3.89 & 4.11 (2s, 6H, 2OCH3), 6.81 (d,
1H, CH), 7.03 (s, 1H, H-7), 7.10 (d, 1H, CH), 7.67 (d, 1H,
H-3), 7.99 ppm (d, 1H, H-2). 13C NMR (125 MHz, DMSO-
d6, 25 C, TMS): d= 21.0 (CH3), 56.2 & 59.9 (2OCH3), 89.7
(C-7), 104.1–156.7 (Ar–C), 201.1 ppm (C‚O). Anal. For
C15H14N2O4 (286.28) calcd: C 62.93, H 4.93, N 9.79. Found:
C 62.77, H 4.74, N 9.55.
2.1.6. 5-(4,6-Dimethoxybenzofuran-5-yl)-1-phenyl-1H-pyrazole (7)
A mixture of compound 4 (0.53 g, 0.002 mol) and phenylhydr-
azine (0.22 g, 0.002 mol) in absolute ethanol (15 mL) contain-
ing few drops of glacial acetic acid was reﬂuxed for 3 h. After
cooling, the reaction mixture was poured onto water (20 mL)
and the solid that formed was ﬁltered off, air dried and recrys-
tallized from methanol. Yield 45 %, m.p. 81–3 C. IR (KBr): m
1621 (C‚N), 1599 (C‚C), 1011, 1009, 1001 cm1 (C–O–C).
1H NMR (500 MHz, DMSO-d6, 25 C, TMS): d= 2.89 &
3.99 (2s, 6H, 2OCH3), 6.81 (d, 1H, CH), 7.00 (s, 5H, Ph–H),
7.03 (s, 1H, H-7), 7.23 (d, 1H, CH), 7.44 (d, 1H, H-3),
7.98 ppm (d, 1H, H-2). 13C NMR (125 MHz, DMSO-d6,
25 C, TMS): d= 56.2 & 59.9 (2OCH3), 89.7 (C-7), 111.1–
155.3 ppm (Ar–C). Anal. For C19H16N2O3 (320.34) calcd: C
71.24, H 5.03, N 8.74. Found: C 71.44, H 4.94, N 8.55.
2.1.7. 5-(4,6-Dimethoxybenzofuran-5-yl)-1-benzyl-1H-pyrazole (8)
A mixture of compound 4 (0.53 g, 0.002 mol), benzylhydrazine
dihydrochloride (0.39 g, 0.002 mol) and sodium acetate (0.3 g,
0.004 mol) in absolute ethanol (15 mL) was reﬂuxed for 3 h.
After cooling, the reaction mixture was poured onto water
(20 mL) and the solid that formed was ﬁltered off, air dried
and recrystallized from absolute ethanol. Yield 80 %, m.p.
89–91˚C. IR (KBr): m 1620 (C‚N), 1555 (C‚C), 1011, 1009,
1001 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-d6, 25 C,
TMS): d= 3.80 & 4.04 (2s, 6H, 2OCH3), 4.56 (s, 2H, CH2),
6.81 (d, 1H, CH), 7.05 (s, 1H, H-7), 7.18 (d, 1H, CH), 7.27
(d, 1H, H-3), 7.29 (s, 5H, Ph–H), 7.89 ppm (d, 1H, H-2). 13C
NMR (125 MHz, DMSO-d6, 25 C, TMS): d= 32.4 (CH2),
56.2 & 57.2 (2OCH3), 89.7 (C-7), 105.3–161.4 ppm (Ar–C).
Anal. For C20H18N2O3 (334.37) calcd: C 71.84, H 5.43, N
8.38. Found: C 71.71, H 5.25, N 8.51.2.1.8. 6-(4,6-Dimethoxybenzofuran-5-yl)pyrimidine-2(1H)-thione
(9)
A mixture of compound 4 (0.53 g, 0.002 mol) and thiourea
(0.15 g, 0.002 mol) in absolute ethanol (15 mL) containing
few drops of glacial acetic acid (0.5 mL) was reﬂuxed for 2 h.After cooling, the reaction mixture was poured onto ice-water
(50 mL) and the solid that formed was ﬁltered off, air dried
and recrystallized from absolute ethanol. Yield 92 %, m.p.
110–2 C. IR (KBr): m 3162 (NH), 1615 (C‚N), 1573
(C‚C), 1248 (C‚S), 1169, 1097, 1028 cm1 (C–O–C). 1H
NMR (500 MHz, DMSO-d6, 25 C, TMS): d= 3.80 & 4.03
(2s, 6H, 2OCH3), 7.04 (s, 1H, H-7), 7.18 & 7.27 (2d, 2H,
2CH), 7.44 (d, 1H, H-3), 7.89 (d, 1H, H-2), 11.12 ppm (s,
1H, NH). 13C NMR (125 MHz, DMSO-d6, 25 C, TMS):
d= 56.2 & 57.2 (2OCH3), 89.7 (C-7), 105.3–161.4 ppm (Ar–
C). Anal. For C14H12N2O3S (288.32) calcd: C 58.32, H 4.20,
N 9.72. Found: C 58.45, H 4.44, N 9.52.
2.1.9. 6-(4,6-Dimethoxybenzofuran-5-yl)pyrimidin-2(1H)-one
(10)
A mixture of compound 4 (0.53 g, 0.002 mol) and urea (0.12 g,
0.002 mol) in absolute ethanol (15 mL) containing few drops
of glacial acetic acid (0.5 mL) was reﬂuxed for 2 h. After cool-
ing, the reaction mixture was poured onto ice-water (50 mL)
and the solid that formed was ﬁltered off, air dried and recrys-
tallized from absolute ethanol. Yield 85 %, m.p. 99–102 C. IR
(KBr): m 3107 (NH), 1676 (C‚O), 1641 (C‚N), 1609 (C‚C),
1153, 1075, 1007 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-
d6, 25 C, TMS): d= 3.80 & 4.04 (2s, 6H, 2OCH3), 7.05 (s,
1H, H-7), 7.18 & 7.27 (2d, 2H, 2CH), 7.29 (d, 1H, H-3), 7.89
(d, 1H, H-2), 10.92 ppm (s, 1H, NH). 13C NMR (125 MHz,
DMSO-d6, 25 C, TMS): d= 56.2 & 57.2 (2OCH3), 89.7 (C-
7), 105.3–157.4 (Ar–C), 201.1 ppm (C‚O). Anal. For
C14H12N2O4 (272.26) calcd: C 61.76, H 4.44, N 10.29. Found:
C 61.55, H 4.22, N 10.01.
2.1.10. 4-(4,6-Dimethoxybenzofuran-5-yl)pyrimidin-2-amine
(11)
A mixture of compound 4 (2.66 g, 0.01 mol), guanidine
hydrochloride (0.96 g, 0.01 mol) and anhydrous sodium ace-
tate (0.82 g, 0.01 mol) in absolute ethanol (15 mL) was re-
ﬂuxed for 2–3 h. The solid that formed while hot was
ﬁltered off, washed with water, air dried and recrystallized
from absolute ethanol. Yield 40 %, m.p. 47–9 C. IR
(KBr): m 3161 & 3122 (NH2), 1616 (C‚N), 1578 (C‚C),
1103, 1022 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-d6,
25 C, TMS): d= 3.80 & 4.04 (2s, 6H, 2OCH3), 5.56 (s,
2H, NH2), 7.05 (s, 1H, H-7), 7.27 & 7.54 (2d, 2H, 2CH),
7.84 (d, 1H, H-3), 8.09 ppm (d, 1H, H-2). 13C NMR
(125 MHz, DMSO-d6, 25 C, TMS): d= 56.2 & 58.7
(2OCH3), 89.7 (C-7), 104.3–157.4 ppm (Ar–C). Anal. For
C14H13N3O3 (271.27) calcd: C 61.99, H 4.83, N 15.49.
Found: C 62.11, H 5.00, N 15.32.
2.1.11. N-(4-(4,6-Dimethoxybenzofuran-5-yl)pyrimidin-2-yl)
acetamide (12)
A solution of compound 11 (0.54 g, 0.002 mol) in a mixture of
(10 mL) acetic anhydride and glacial acetic acid (2:1) was
heated under reﬂux for 10 h. After cooling, the reaction mix-
ture was poured onto ice-water (50 mL), and the solid that
formed was ﬁltered off, air dried and recrystallized from aque-
ous ethanol. Yield 78 %, m.p. 161–3 C. IR (KBr): m 3100
(NH), 1698 (C‚O), 1622 (C‚N), 1601 (C‚C), 1011, 1009,
1001 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-d6, 25 C,
TMS): d= 2.10 (s, 1H, NH), 3.2 (s, 3H, CH3), 3.80 & 4.04
(2s, 6H, 2OCH3), 7.05 (s, 1H, H-7), 7.27 & 7.54 (2d, 2H,
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(125 MHz, DMSO-d6, 25 C, TMS): d= 23.1 (CH3), 56.2 &
58.7 (2OCH3), 89.7 (C-7), 104.3–157.4 (Ar–C), 175.1 ppm
(C‚O). Anal. For C16H15N3O4 (313.31) calcd: C 61.34, H
4.83, N 13.41. Found: C 61.50, H 4.61, N 13.55.
2.1.12. N-(4-(4,6-Dimethoxybenzofuran-5-yl)pyrimidin-2-yl)-
2-benzamide (13)
A mixture of compound 11 (0.54 g, 0.002 mol) and benzoyl
chloride (0.002 mol) in dry dioxane containing triethylamine
(1 mL) was reﬂuxed for 3 h. After cooling, the reaction mixture
was poured onto water (30 mL) and the solid that formed was
ﬁltered off, air dried and recrystallized from absolute ethanol.
Yield 60 %, m.p. 72–4 C. IR (KBr): m 3150 (NH), 1678
(C‚OO), 1622 (C‚ON), 1599 (C‚OC), 1011, 1009,
1001 cm1 (C–O–C). 1H NMR (500 MHz, DMSO-d6, 25 C,
TMS): d= 2.32 (s, 1H, NH), 3.80 & 4.04 (2s, 6H, 2OCH3),
7.01 (s, 5H, Ph–H), 7.05 (s, 1H, H-7), 7.27 & 7.54 (2d, 2H,
2CH), 7.77 (d, 1H, H-3), 8.09 ppm (d, 1H, H-2). Anal. For
C21H17N3O4 (375.38) calcd: C 67.19, H 4.56, N 11.19. Found:
C 67.44, H 4.60, N 11.27.
2.1.13. N-(4-(4,6-Dimethoxybenzofuran-5-yl)pyrimidin-2-yl)-
2-benzenesulphonamide (14)
A mixture of compound 11 (0.54 g, 0.002 mol) and benzenesul-
phonyl chloride (0.002 mol) in dry dioxane (15 mL) containing
triethylamine (1 mL) was reﬂuxed for 3 h. After cooling, the
reaction mixture was poured onto water (30 mL) and the solid
that formed was ﬁltered off, air dried and recrystallized from
absolute ethanol. Yield 62 %, m.p. 85–7 C. IR (KBr): m
3180 (NH), 1622 (C‚ON), 1565 (C‚OC), 1375 & 1150
(SO2), 1011, 1009, 1001 cm
1 (C–O–C). 1H NMR (500 MHz,
DMSO-d6, 25 C, TMS): d= 2.31 (s, 1H, NH), 3.80 & 4.04
(2s, 6H, 2OCH3), 7.01 (s, 5H, Ph–H), 7.08 (s, 1H, H-7), 7.27
& 7.54 (2d, 2H, 2CH), 7.77 (d, 1H, H-3), 7.98 ppm (d, 1H,
H-2). Anal. For C20H17N3O5S (411.43) calcd: C 58.38, H
4.16, N 10.21. Found: C 58.50, H 4.25, N 10.44.
2.1.14. 4-(4,6-Dimethoxybenzofuran-5-yl)-2-azidopyrimidine
(15)
To a cooled solution of compound 11 (5.42 g, 0.02 mol) in con-
centrated sulphuric acid (5 mL) and ice (15 g), cooled solution
of sodium nitrite (1.73 g, 0.025 mol) in ice-water (10 mL) was
added dropwise while stirring at 0–5 C and keeping at this
temperature for 10 min. To the solution of diazonium salt, so-
dium azide (1.3 g, 0.02 mol) in ice-water (5 mL) was added
dropwise while stirring. The solution was left at room temper-
ature for 15 min then the azide was extracted by diethyl ether.
Ether was evaporated in vacuo and azide was used without
subsequent cleaning. 2-Azidopyrimidine derivative (15) was
identiﬁed by chromatography mass spectrometry since it
decomposed slowly during the preparation of the analyzed
sample. Also, it is used in the reaction immediately after its for-
mation because of its instability. Yield 71 %, m.p. 120–2 C.
MS, m/z (%): 297 for C14H11N5O3 (M
+, 2), 225 (100).
2.1.15. 5-Methyl-1-(4-(4,6-dimethoxybenzofuran-5-yl)pyrimidin-
2-yl)-1H-1,2,3-triazole-4-carboxylic acid (16)
To a solution of sodium (0.23 g, 0.01 mol) in absolute metha-
nol (20 mL) were added ethyl acetoacetate (1.34 g, 0.01 mol)and 2-azidopyrimidine 15 (2.71 g, 0.01 mol) dropwise while
stirring and cooling in an ice-bath. The reaction mixture was
kept in an ice water bath for 30 min and then gradually heated
under reﬂux for 1 h. After cooling, the reaction mixture was
neutralized by diluted hydrochloric acid (1:1). The solid that
formed was ﬁltered off, washed with water, air dried and
recrystallized from methanol. Yield 63 %, m.p. 178–180 C.
IR (KBr): m 4300 (OH), 1645 (C‚O), 1622 (C‚N), 1578
(C‚C), 1009, 1001 cm1 (C–O–C). 1H NMR (500 MHz,
DMSO-d6, 25 C, TMS): d= 2.31 (s, 3H, CH3), 3.80 & 4.04
(2s, 6H, 2OCH3), 7.08 (s, 1H, H-7), 7.27 & 7.54 (2d, 2H,
2CH), 7.77 (d, 1H, H-3), 7.98 (d, 1H, H-2), 12.10 ppm (s,
1H, OH). Anal. For C18H15N5O5 (381.34) calcd: C 56.69, H
3.96, N 18.37. Found: C 56.44, H 4.01, N 18.50.
2.1.16. N-(p-Nitrobenzylidene)-4-(4,6-dimethoxybenzofuran-5-
yl) pyrimidine-2-amine (17)
A mixture of compound 11 (0.81 g, 0.003 mol) and p-nitro-
benzaldehyde (0.45 g, 0.003 mol) in absolute ethanol (20 mL)
containing glacial acetic acid (1 mL) was reﬂuxed for 3 h. After
cooling, the reaction mixture was poured onto water (30 mL)
and the solid that formed was ﬁltered off, air dried and recrys-
tallized from absolute ethanol. Yield 93 %, m.p. 79–81 C. IR
(KBr): m 1645 (C‚N), 1589 (C‚C), 1012, 1009, 1001 (C–O–C)
cm1. 1H NMR (500 MHz, DMSO-d6, 25 C, TMS): d= 3.80
& 4.04 (2s, 6H, 2OCH3), 7.08 (s, 1H, H-7), 7.27 (d, 1H, CH),
7.29–7.56 (m, 4H, Ph–H), 7.62 (d, 1H, CH), 7.77 (d, 1H, H-3),
7.98 (d, 1H, H-2), 8.57 (s, 1H, CH‚N) ppm. Anal. For
C21H16N4O5 (404.38) calcd: C 62.37, H 3.99, N 13.86. Found:
C 62.55, H 4.02, N 14.00.
2.1.17. 3-(4-(4,6-Dimethoxybenzofuran-5-yl)pyrimidin-2-yl)-2-
(p-nitrophenyl)thiazolidin-4-one (18)
To a stirred solution of compound 17 (0.81 g, 0.002 mol) in dry
dioxane (25 mL) was added thioglycolic acid (0.024 g,
0.003 mol). After stirring for 4 h, anhydrous sodium sulphate
(5 g) was added and then reﬂuxed for 6 h. The reaction mixture
was ﬁltered while hot. After cooling, the solid that obtained
was ﬁltered off, washed with water, air dried and recrystallized
from dioxane. Yield 79 %, m.p. 94–6 C. IR (KBr): m 1670
(C‚O), 1622 (C‚N), 1576 (C‚C), 1012, 1009, 1001 cm1
(C–O–C). 1H NMR (500 MHz, DMSO-d6, 25 C, TMS):
d= 3.31 (s, 2H, CH2), 3.80 & 4.04 (2s, 6H, 2OCH3), 5.61 (s,
1H, CH), 7.08 (s, 1H, H-7), 7.27 (d, 1H, CH), 7.29–7.56 (m,
4H, Ph–H), 7.62 (d, 1H, CH), 7.77 (d, 1H, H-3), 7.98 ppm
(d, 1H, H-2). Anal. For C23H18N4O6S (478.48) calcd: C
57.73, H 3.79, N 11.71. Found: C 57.62, H 4.00, N 11.55.
2.1.18. 3-Chloro-1-(4-(4,6-dimethoxybenzofuran-5-
yl)pyrimidin-2-yl)-4-(p-nitrophenyl)azetidin-2-one (19)
A solution of compound 17 (0.81 g, 0.002 mol) and triethyl-
amine (0.5 mL) in dry benzene (50 mL) was cooled and stirred.
To this well-stirred cooled solution chloroacetyl chloride
(0.004 mol) was added dropwise within a period of 20 min,
and then the reaction mixture was stirred for an additional
3 h and left at room temperature for 48 h. The reaction mix-
ture was poured onto water (30 mL) and the solid that formed
was ﬁltered off, air dried and recrystallized from n-hexane.
Yield 71%, m.p. 226–8 C. IR (KBr): m 1665 (C‚O), 1621
(C‚N), 1578 (C‚C), 1010, 1009, 1001 cm1 (C–O–C), 745
(Cl). 1H NMR (500 MHz, DMSO-d6, 25 C, TMS): d= 3.80
918 E.R. El-Sawy et al.& 4.04 (2s, 6H, 2OCH3), 4.99 (s, 1H, CH), 5.61 (d, 1H, CH),
7.08 (s, 1H, H-7), 7.27 (d, 1H, CH), 7.29–7.56 (m, 4H,
Ph–H), 7.62 (d, 1H, CH), 7.77 (d, 1H, H-3), 7.98 ppm
(d, 1H, H-2). Anal. For C23H17ClN4O6 (480.86) calcd: C
57.45, H 3.56, N 11.65. Found: C 57.22, H 3.66, N 11.82.
2.2. Biological assays
2.2.1. Animals
Adult male albino rats (Harlan Sprague–Dawley, USA), weigh-
ing 150–180 g were used for the evaluation of the anti-inﬂam-
matory activity. Animals were fasted for 12 h before the
assay. Adult Swiss Webster mice of both sexes (Harlan Spra-
gue–Dawley, USA), weighing 20–25 g were fasted for 12–24 h
and used for the assessment of the analgesic and anticonvulsant
activities. All animals were obtained from the animal house
colony of the National Research Centre, Cairo, Egypt. Animals
were allowed free access to water and fed with standard
diet. The research was conducted in accordance with the
ethical rules on animal experimentation, approved by the
Ethics Committee of the National Research Centre, Cairo,
Egypt.
2.2.2. Anti-inﬂammatory activity
Evaluation of the anti-inﬂammatory activity was performed
using carrageenean-induced rat paw oedema model according
to the method of (Obukowicz et al., 1998). The animals were
divided into groups (control, reference and test groups, each
of 8 animals. Acute inﬂammation was produced by subplantar
injection of 0.05 mL of 1 % suspension of carrageenean in sal-
ine into the plantar tissue of one (right) hind paw of the rat,
one hour after oral administration of the test compound at
dose levels of 20 and 5 mg kg1. The control group received
equal volume of saline into the other (left) hind paw. The ref-
erence group was orally administered with ﬂufenamic acid
(20 mg kg1) and indomethacin (5 mg kg1) suspended in sal-
ine as reference drugs. The average mass of oedema was esti-
mated for control, reference and the test groups four hours
after drug administration. The inhibitory activity (percentage
of inhibition of oedema) was evaluated (Winter et al., 1963).
The results were analyzed for statistical signiﬁcance (ex-
pressed as mean ± SEM) between the vehicle control and
the treated groups using one-way ANOVA followed by multi-
ple comparisons by Duncan’s multiple range tests.
2.2.3. Analgesic activity
It was studied using p-benzoquinone-induced writhing model
in mice according to the method described by Okun et al.
(1963). The test compounds and the reference drugs ﬂufenamic
acid and indomethacine were prepared as a suspension in 2 %
Tween 80. A sensitivity test was carried out one day before
drug administration when the animals were injected (i.p.) with
0.2–0.25 mL of 0.02 % freshly prepared solution of p-benzo-
quinone in distilled water. Animals showing writhing to p-
benzoquinone within 30 min were chosen for studying the
analgesic activity. On the following day, mice were divided into
13 groups each of 6 animals, and the drugs were administered
according to the following protocol: the ﬁrst group received
2% Tween 80 (solvent/negative control), the second group re-
ceived ﬂufenamic acid as a reference (20 mg kg1), the third
group received indomethacine as a reference (5 mg kg1), whilethe other groups received two doses of the test compounds (20
and 5 mg kg1). One hour later, 0.02% solution of p-benzoqui-
none was administered (i.p.). The animals were observed for
30 min after injection of the irritant during which the animals
showing writhing were counted (writhing is deﬁned as stretch,
torsion to one side, drawing up of hind leg, retraction of the
abdomen, so that the belly of mouse touches the ﬂoor). All
writhing is considered as a positive response. The analgesic
activity was expressed as the percent protection.
2.2.4. Anticonvulsant activity
The electric shock seizure test (Vogel and Vogel, 1997) was ta-
ken as criteria for the evaluation of the anticonvulsant
activity. Mice were injected intraperitoneally with 2% Tween
80 (solvent/negative control) and 5 mg kg1 diazepam (refer-
ence drug). The other groups received two doses (25 and
12.5 mg kg1) of each test compound. One hour after the
drug administration, animals were stimulated through ear
electrode of 50 mA as a signal stimulator for 0.2 s. The charac-
teristics of electric shock seizure are a tonic limb ﬂexion of 1–
2 s, followed by a tonic limb extension of roughly 10–12 s, and
ﬁnally generalized clonic movement for 12 s. Only abolishment
of the hind limb tonic extensor spasm is recorded as the
measure of anticonvulsant potency. The tonic component is
considered abolished if the hind leg extension does not exceed
a 90 angle with the plane of the body. Animals showing
protection against convulsion were counted in each group.
The anticonvulsant activity was expressed as the percent
protection.
3. Results and discussion
3.1. Chemistry
The synthetic route for the preparation of the target com-
pounds is illustrated in Scheme 1–3. Condensation reaction
of 1-(4,6-dimethoxybenzofuran-5-yl)ethanone (1) (Schonberg
et al., 1953) with phenylhydrazine in glacial acetic acid
led to the formation of the corresponding 1-(1-(4,6-
dimethoxybenzofuran-5-yl)ethylidene)-2-phenylhydrazine (2)
(Scheme 1). Vilsmeier–Haack reaction of the latter hydrazone
2 using 2.5 equivalent moles of Vilsmeier reagent (DMF/
POCl3) preformed double addition of reagent on the methyl
group to afford ultimately after hydrolysis, the cyclize pyra-
zole-4-carboxaldehyde derivative 3 with good yield 84%
(Scheme 1). The IR spectrum of compound 3 showed strong
absorption bands at 1705 cm1 characteristic for C‚O of
the aldehyde group. Its 1H NMR spectrum lacks the presence
of CH3 protons of hydrazone 2 and revealed new singlet signal
at 9.55 ppm for CHO proton besides H-5 of pyrazole at
9.02 ppm. In addition, 13C NMR spectrum revealed signal at
201.1 ppm for (C‚O). Its mass spectrum showed molecular
ion peaks at m/z (%) = 348 (2) (c.f. Section 2).
On the other hand, reaction of compound 1 with 2.5 equiv-
alent moles of Vilsmeier reagent (DMF/POCl3) under heating
at 60 C for 3 h (Vilsmeier Haack Arnold reaction) led to the
formation of 3-chloro-3-(4,6-dimethoxybenzofuran-5-yl)pro-
penal (4) in 30% yield (Scheme 1).
Although there is very low yield of compound 4 it seems to
have some interest due to the presence of a,b-bifunctional
chloro and aldehyde groups. Reaction of compound 4 with
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Synthesis, anti-inﬂammatory, analgesic and anticonvulsant activities 919hydrazine hydrate in absolute ethanol and in the presence
of few drops of glacial acetic acid afforded 5-(4,6-dim-
ethoxybenzofuran-5-yl)-1H-pyrazole (5). Whereas, reaction
of compound 4 with hydrazine hydrate under reﬂux in amixture of acetic anhydride and glacial acetic acid (2:1) affor-
ded, the corresponding N-acetylpyrazole derivative (6)
(Scheme 2). Additionally, reaction of compound 4 with phen-
ylhydrazine gave N-phenylpyrazole derivative 7. While, reac-
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920 E.R. El-Sawy et al.tion of compound 4 with benzylhydrazine dihydrochloride in
the presence of anhydrous sodium acetate gave N-benzylpyraz-
ole derivative 8 (Scheme 2).
Furthermore, reaction of compound 4 with thiourea and/
or urea in absolute ethanol in the presence of glacial acetic
acid as a catalyst gave 6-(4,6-dimethoxybenzofuran-5-yl)
pyrimidin-2(1H)-thione (9) and 6-(4,6-dimethoxybenzofuran-
5-yl)pyrimidin-2(1H)-one (10), respectively. Moreover,
reaction of compound 4 with guanidine hydrochloride in
absolute ethanol in the presence of anhydrous sodium acetate
yielded 6-(4,6-dimethoxybenzofuran-5-yl)pyrimidin-2-amine
(11) (Scheme 2).
Upon heating of 2-aminopyrimidine derivative (11) in a
mixture of acetic anhydride and glacial acetic acid (2:1) led
to the formation of N-(4-(4,6-dimethoxybenzofuran-5-yl)pyr-
imidin-2-yl)acetamide (12) (Scheme 3). On the other hand,
reaction of compound (11) with benzoyl chloride and/or
benzenesulphonyl chloride in dry dioxane and in the pres-
ence of triethylamine as a base afforded N-benzamide deriv-
atives 13 and N-sulphonamide derivatives 14, respectively
(Scheme 3).
Diazotization of 2-aminopyrimidine derivative (11) with
concentrated sulphuric acid and sodium nitrite at 0–5 Cyielded the corresponding diazonium salt which, upon reaction
with sodium azide yielded 2-azidopyrimidine derivative (15)
(Scheme 3).
It was previously reported that, organic azide undergoes
base catalyzed condensation reaction with activated methylen-
ic compound giving rise to the 1,2,3-triazole moiety (Pokhod-
ylo et al., 2009). In the present work and under the above
mentioned conditions, the new azidopyrimidine derivative
(15) was allowed to react with ethyl acetoacetate in the
presence of sodium methoxide and give the corresponding
5-methyl-1-(4-(4,6-dimethoxybenzofuran-5-yl)pyrimidin-2-yl)-
1H-1,2,3-triazole-4-carboxylic acid (16) in 63% good yield
(Scheme 3).
Acid catalyzed reaction of compound (11) with p-nitro-
benzaldehyde in absolute ethanol yielded the corresponding
Schiff base 17 (Scheme 3). Cyclocondensation of Schiff base
17 with thioglycollic acid in the presence of anhydrous sodium
sulphate yielded 3-(4-(4,6-dimethoxybenzofuran-5-yl)pyrimi-
din-2-yl)-2-(p-nitrophenyl)thiazolidin-4-one (18). On the other
hand, reaction of Schiff base 17 with chloroacetyl chloride in
the presence of triethylamine afforded 3-chloro-1-(4-(4,6-dim-
ethoxybenzofuran-5-yl)pyrimidin-2-yl)-4-(p-nitrophenyl) azeti-
din-2-one (19) (Scheme 3).
Synthesis, anti-inﬂammatory, analgesic and anticonvulsant activities 921The structures of the newly synthesized compounds were
conﬁrmed on the basis of elemental analyses as well as IR,
NMR, and MS spectral data (c.f. Section 2).
3.2. Biological activity
The newly synthesized compounds were evaluated for their
anti-inﬂammatory activity against carrageenan-induced rat
paw oedema by administration of 20 and 5 mg kg1 (p.o.)
using ﬂufenamic acid (20 mg kg1) and indomethacin
(5 mg kg1) as reference drugs. The data obtained (Table 1) re-
vealed that, paw oedema was inhibited by the oral administra-
tion of the most of the test compounds at a dose level of
20 mg kg1. The most active test compounds were in the
descending order of 5 > 6, 11 > 8 > 7> 12 > 17 with inhi-Table 2 Effect of the newly synthesized compounds on p-benzoqui
Compd. no. Dose
(mg kg1)
Inhibition
(%)
5 20 83
5 50
6 20 66
5 33
7 20 66
5 33
8 20 66
5 33
9 20 50
5 33
10 20 50
5 33
11 20 50
5 33
12 20 40
5 16
a 2% Tween 80 is a respective control and solvent for tested compound
Table 1 Effect of the newly synthesized compounds on carrageena
Compd. no. Dose
(mg kg1)
Inhibition
(%)
5 5 39
20 50
6 5 33
20 45
7 5 33
20 42
8 5 32
20 44
9 5 19
20 33
10 5 22
20 37
11 5 19
20 45
12 5 19
20 39
a Saline is a respective control and solvent for test compounds and refebition effect ranging from 50% to 39% compared to ﬂufen-
amic acid (53%) at a dose of 20 mg kg1 and indomethacin
(51%) at a dose of 5 mg kg1. The existence of pyrazole moiety
at position-5 of benzofuran as in compounds 5 and 6 or pyrim-
idine moiety as in compound 11 showed inhibitions of 50%,
45% and 45% nearly to the reference ﬂufenamic acid (53%).
Only, compounds 5, 6, 7, 8 and 17 exhibit inhibition effects
of 39%, 33%, and 32% at a dose of 5 mg kg1 compared to
indomethacin (51%) at a dose of 5 mg kg1.
The analgesic activity of the investigated synthesized com-
pounds was studied using p-benzoquinone induced writhing re-
sponse in mice. The obtained data (Table 2) indicated that,
compound 5 showed equipotent writhing inhibition of 83%
as compared to the reference drug ﬂufenamic acid (83%) at
a dose of 20 mg kg1. Compounds 6, 7 and 8 at a dose ofnone induced writhing response in mice.
Compd. no. Dose
(mg kg1)
Inhibition
(%)
13 20 30
5 5
14 20 42
5 16
16 20 42
5 33
17 20 42
5 16
18 20 33
5 16
19 20 33
5 16
Negative controla 0 0
Flufenamic acid 20 83
Indomethacin 5 66
s and reference drugs (ﬂufenamic acid and indomethacin).
n induced rat paw oedema.
Compd. no. Dose
(mg kg1)
Inhibition
(%)
13 5 27
20 33
14 5 20
20 32
16 5 26
20 33
17 5 32
20 39
18 5 20
20 32
19 5 16
20 33
Negative controla 0 0
Indomethacin 5 51
Flufenamic acid 20 53
rence drugs (ﬂufenamic acid and indomethacin).
Table 3 Anticonvulsant activity of the newly synthesized compounds.
Compd. no. Dose
(mg kg1)
Protection
(%)
Compd. no. Dose
(mg kg1)
Protection
(%)
5 25 83 13 25 42
12.5 45 12.5 16
6 25 50 14 25 40
12.5 33 12.5 22
7 25 66 16 25 33
12.5 33 12.5 16
8 25 50 17 25 66
12.5 33 12.5 33
9 25 50 18 25 33
12.5 27 12.5 16
10 25 42 19 25 33
12.5 22 12.5 16
11 25 50 Negative controla 0 0
12.5 16
12 25 50 Diazepam 5 50
12.5 33
a 2% Tween 80 is a respective control and solvent for tested compounds and diazepam.
922 E.R. El-Sawy et al.5 mg kg1 showed equipotent writhing inhibition of 66% as
compared to the reference drug indomethacin at a dose of
5 mg kg1. On the other hand, the most active test compounds
were in the descending order of 5> 6, 7 and 8> 9, 10 and 11
with writhing inhibition of 66%, 50% and 42% compared to
ﬂufenamic acid (83%) at a dose of 20 mg kg1. Also, the most
active test compounds were in the descending order of 5> 6,
7, 8, 9, 10, 11 and 16 with writhing inhibitions of 50% and
33% compared to indomethacin at a dose of 5 mg kg1. From
the data obtained, the writhing inhibitions of the newly synthe-
sized compounds seem to relate with the presence of pyrazole
and pyrimidine moieties at these compounds.
The anticonvulsant properties of the tested compounds
were studied using diazepam as reference which showed %
protection of 50 in a dose of 5 mg kg1 (Table 3). Data ob-
tained revealed that, compounds 6, 8, 9, 11 and 12 at a dose
level of 25 mg kg1 showed anticonvulsant protection (50%)
as did the reference drug diazepam at 5 mg kg1, while com-
pounds 5, 7 and 17 at a dose level of 25 mg kg1 exhibited
higher protection (66–83%) compared to diazepam at
5 mg kg1. Compound 5 at a dose level of 25 and
12.5 mg kg1, respectively, was found to be the most potent
compound as it induced 83% and 45% protection compared
to diazepam (5 mg kg1) which caused 50% protection.Acknowledgment
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